GlassScriptPhysician profile
Neil A Levin
NPI 1285633081
$4,044.32
in general payments reported to CMS, 2019-2025
33 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $1,352 · 2021: $112 · 2022: $348 · 2023: $993 · 2024: $123 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $836.00 | 2019-2025 | |
| Amgen INC. | $754.44 | 2019-2022 | |
| Novo Nordisk INC | $261.94 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.47 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $213.26 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $202.21 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $193.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $141.57 | 2019-2023 | Breztri |
| Lilly USA, LLC | $138.31 | 2019-2023 | Emgality, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $136.09 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $122.66 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $110.72 | 2019-2020 | |
| Abbvie INC. | $81.34 | 2023-2025 | |
| Radius Health, INC. | $60.97 | 2019-2020 | |
| Amarin Pharma, INC. | $59.40 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $49.70 | 2023 | Ingrezza, Ongentys |
| Medtronic, INC. | $48.68 | 2023 | Linq II |
| Kowa Pharmaceuticals America, INC. | $47.33 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $39.63 | 2019 | |
| Sanofi Pasteur INC. | $38.93 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.65 | 2023 | |
| Eisai INC. | $23.17 | 2020 | |
| Boston Scientific Corporation | $22.96 | 2023 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company LTD. | $22.88 | 2022 | |
| Hologic Sales and Service, LLC | $22.38 | 2020 | |
| Alnylam Pharmaceuticals INC. | $22.17 | 2023 | Givlaari |
| Abbott Laboratories | $18.52 | 2023 | Proclaim |
| Xeris Pharmaceuticals, INC. | $16.59 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $16.13 | 2023 | Rexulti |
| Exact Sciences Corporation | $15.33 | 2025 | The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $13.78 | 2019 | |
| Concordia Pharmaceuticals INC. | $13.50 | 2019 | |
| Allergan, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.